scholarly journals Preoperative anaemia and red blood cell transfusion in patients with aneurysmal subarachnoid and intracerebral haemorrhage – A multicentre subanalysis of the German PBM Network Registry

Author(s):  
Elke Schmitt ◽  
Patrick Meybohm ◽  
Vanessa Neef ◽  
Peter Baumgarten ◽  
Alexandra Bayer ◽  
...  

Abstract Purpose Anaemia is common in patients presenting with aneurysmal subarachnoid (aSAH) and intracerebral haemorrhage (ICH). In surgical patients, anaemia was identified as an idenpendent risk factor for postoperative mortality, prolonged hospital length of stay (LOS) and increased risk of red blood cell (RBC) transfusion. This multicentre cohort observation study describes the incidence and effects of preoperative anaemia in this critical patient collective for a 10-year period. Methods This multicentre observational study included adult in-hospital surgical patients diagnosed with aSAH or ICH of 21 German hospitals (discharged from 1 January 2010 until 30 September 2020). Descriptive, univariate and multivariate analyses were performed to investigate the incidence and association of preoperative anaemia with RBC transfusion, in-hospital mortality and postoperative complications in patients with aSAH and ICH. Results A total of n = 9,081 patients were analysed (aSAH n = 5,008; ICH n = 4,073). Preoperative anaemia was present at 28.3% in aSAH and 40.9% in ICH. RBC transfusion rates were 29.9% in aSAH and 29.3% in ICH. Multivariate analysis revealed that preoperative anaemia is associated with a higher risk for RBC transfusion (OR= 3.25 in aSAH, OR = 4.16 in ICH, p < 0.001), for in-hospital mortality (OR= 1.48 in aSAH, OR= 1.53 in ICH, p < 0.001) and for several postoperative complications. Conclusions Preoperative anaemia is associated with increased RBC transfusion rates, in-hospital mortality and postoperative complications in patients with aSAH and ICH. Trial registration: ClinicalTrials.gov, NCT02147795, https://clinicaltrials.gov/ct2/show/NCT02147795

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Chen Wang ◽  
Isabelle Le Ray ◽  
Brian Lee ◽  
Agneta Wikman ◽  
Marie Reilly

Abstract The increased risk of venous thromboembolism (VTE) associated with pregnancy is well-known and prophylaxis guidelines consider a number of risk factors. Although non-O blood group and red blood cell (RBC) transfusion are known to be associated with VTE risk, their contribution to pregnancy-associated VTE has received little attention. This study was conducted in a population-based cohort of 1,000,997 deliveries to women with no prior history of VTE or thrombophilia. The independent contributions of ABO blood type and RBC transfusion to the risks of antepartum, peripartum and postpartum VTE are reported as odds ratios adjusted for risk factors that are considered in current prophylaxis guidelines and other potential confounders. Compared with type O, A and B blood types have higher risk of antepartum and postpartum VTE, with odds ratios between 1.4 and 1.8. Transfusion around delivery has the largest increased risks and a dose-response effect, with adjusted odds ratios from 2.60 (1.71–3.97) for 1–2 units to 3.55 (1.32–9.55) for more than 5 units. ABO blood type and RBC transfusion were found to be independent risk factors for pregnancy-associated VTE. Further research is required to understand the underlying mechanisms and to conduct a risk-benefit assessment of the small volumes of RBCs transfused around delivery.


2021 ◽  
Author(s):  
Xiaohong Fang ◽  
Dali Huang ◽  
Huibin Zeng ◽  
Liping Xu

Abstract Objective This study was designed to assess red blood cell (RBC) transfusion frequency in very-low-birth-weight (VLBW)infants and to understand the relationships between the number of transfusions and the composite risk of bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and mortality. Method: VLBW infants admitted from May 2017 – July 2019 were retrospectively analyzed. Relationships between gestational age (GA), birth weight (BW), numbers of transfusions, and comorbidities were evaluated through Pearson correlation analyses. The relationship between factors of interest (Model 1: GA, BW, comorbidities; Model 2: number of transfusions) and composite risk was assessed via a logistic regression approach. Results Overall,408 VLBW infants were enrolled, of whom 74% underwent at least one RBC transfusion. Infants with a GA < 30 weeks, a BW < 1,250 g, and comorbidities were more likely to require RBC transfusion. Number of transfusions was related to the risk of analyzed composite outcomes, with risk correlating with undergoing > 3 transfusions (OR: 3.275, 95% CI: 1.707–6.275). Conclusion We found that undergoing > 3 RBC transfusions was related to an increased risk of BPD, ROP, or death in VLBW infants.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1376-1376
Author(s):  
Samir Dalia ◽  
Sheila Pascual ◽  
Jorge Castillo

Abstract Abstract 1376 Poster Board I-398 Introduction: A relationship between red blood cell (RBC) transfusions and the subsequent development of NHL has been suggested from previous observational reports. The mechanism is unclear but could be related to the known immunomodulatory effect of blood transfusion. This report is a meta-analysis of such observational studies and helps clarifying the strength of such an association, if any. Methods: We searched MEDLINE from January 1966 through June 2009 for observational studies on the association between RBC transfusions and NHL in adults using the keywords “transfusion” and “lymphoma”. Prospective studies and case control studies that reported relative risks (RR), hazard ratios or odds ratios with 95% confidence intervals (CI) were included. One author (SD) gathered the data and another (JC) reviewed the data. A fixed-effect model (FEM) was used to assess the combined outcome of individual studies while a random-effects model (REM) was used, if needed, to account for heterogeneity between studies. Heterogeneity was evaluated using the Cochrane Q and I2 statistics. Publication bias was assessed by direct observation of a funnel plot as well as trim-and-fill statistics. Quality of the studies was assessed independently by another author (SP) using the Newcastle-Ottawa scale. Results: Our initial search rendered 1830 articles. After reviewing the abstracts, 21 papers were selected, from which 5 prospective and 9 case-control studies were included in the final analysis. Based on case-control studies, cases receiving RBC transfusions were associated with an RR of 1.37 (95% CI 0.94-1.87) of developing NHL (p=0.11); a REM was used given the heterogeneity found between studies (I2=90%; Q=90.9, p<0.0001). No publication bias was found. Based on prospective studies, RBC transfusions had a RR of 1.57 (95% CI 1.23-1.99) of developing NHL (p=0.0003); a REM was used despite finding minimal heterogeneity (I2=34%; Q=7.7, p=0.17). Publication bias analysis found 2 imputed studies, which would have not altered our results. When pooling data from retrospective and prospective studies, RBC transfusions had a RR of 1.43 (95% CI 1.12-1.84; p=0.005); a REM was used given a high degree of heterogeneity (I2=85%; Q=102.0, p<0.0001). No evidence of publication bias was found when pooling all the studies. Conclusions: In both retrospective and prospective studies, there is an increased risk of developing NHL after getting a RBC transfusion. The possibility that non-diagnosed NHL was the initial indication for transfusions is not addressed by our study, limiting the generalization of our conclusions. After pooling the available data, cases were 43% more likely to develop NHL if they had a RBC transfusion. This risk should be considered non-negligible. Our findings confirm the previously reported association between RBC transfusions and the development of NHL, and further emphasize a conservative approach to RBC transfusions. Disclosures: No relevant conflicts of interest to declare.


2020 ◽  
Vol 31 (3) ◽  
pp. 375-382
Author(s):  
Long Tran ◽  
Guri Greiff ◽  
Alexander Wahba ◽  
Hilde Pleym ◽  
Vibeke Videm

Abstract OBJECTIVES Our goal was to investigate long-term mortality associated with red blood cell (RBC) transfusion among patients with anaemia undergoing cardiac surgery when adjusting for known risk factors. METHODS Adults with preoperative anaemia as defined by World Health Organization criteria undergoing open-heart surgery from 2000 through 2017 were included. Cox regression was performed for long-term mortality (30 days–5 years), comparing patients who received ≥1 unit of RBC with those who did not. Unadjusted and multivariable analyses adjusted for risk factors were performed. RESULTS The study included 1859 patients, 1525 (82%) of whom received RBC transfusion. A total of 370 (19.9%) deaths were registered between 30 days and 5 years; 88 patients (23.8%) died between 30 days and 1 year. The unadjusted hazard ratio (HR) associated with RBC transfusion was 2.09 (1.49–2.93, P &lt; 0.001) from 30 days to 5 years postoperatively. The HR for RBC transfusion were 4.70 (1.72–12.81, P = 0.002) and 1.77 (1.23–2.55, P = 0.002) for 30 days–1 year and 1–5 years, respectively. Adjusting for perioperative risk factors, which included postoperative complications, the HR decreased to 1.16 (0.80–1.68, P = 0.43), 1.79 (0.63–5.12, P = 0.28) and 1.11 (0.75–1.65, P = 0.61) for observation time from 30 days to 5 years, 30 days to 1 year and 1 to 5 years, respectively. Results were similar when postoperative complications were excluded from the adjustment variables. CONCLUSIONS No statistically significant association between RBC transfusion and long-term mortality was found when we adjusted for known risk factors. This study suggests that the observed difference in mortality in this patient group is largely due to patient-related risk factors.


2022 ◽  
Vol 8 ◽  
Author(s):  
Preethi Ramachandran ◽  
Mahesh Gajendran ◽  
Abhilash Perisetti ◽  
Karim Osama Elkholy ◽  
Abhishek Chakraborti ◽  
...  

Introduction: Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is causing dramatic morbidity and mortality worldwide. The Red Blood Cell Distribution Width (RDW) has been strongly associated with increased morbidity and mortality in multiple diseases.Objective: To assess if elevated RDW is associated with unfavorable outcomes in hospitalized COVID-19.Methods: We retrospectively studied clinical outcomes of hospitalized COVID-19 patients for their RDW values. In-hospital mortality was defined as primary outcome, while septic shock, need for mechanical ventilation, and length of stay (LOS) were secondary outcomes.Results: A total of 294 COVID-19 patients were finally studied. Overall prevalence of increased RDW was 49.7% (146/294). RDW was associated with increased risk of in-hospital mortality (aOR, 4.6; 95%CI, 1.5-14.6) and septic shock (aOR, 4.6; 95%CI, 1.4-15.1) after adjusting for anemia, ferritin, lactate, and absolute lymphocyte count. The association remained unchanged even after adjusting for other clinical confounders such as age, sex, body mass index, coronary artery disease, hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. No association was found instead with mechanical ventilation and median LOS.Conclusion: Elevated RDW in hospitalized COVID-19 patients is associated with a significantly increased risk of mortality and septic shock.


Author(s):  
Preethi Ramachandran ◽  
Mahesh Gajendran ◽  
Abhilash Perisetti ◽  
Karim Osama Elkholy ◽  
Abhishek Chakraborti ◽  
...  

AbstractIntroductionCoronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is causing dramatic morbidity and mortality worldwide. The Red Blood Cell Distribution Width (RDW) has been strongly associated with increased morbidity and mortality in multiple diseases.ObjectiveTo assess if elevated RDW is associated with unfavorable outcomes in hospitalized COVID-19.MethodsWe retrospectively studied clinical outcomes of hospitalized COVID-19 patients for their RDW values. In-hospital mortality was defined as primary outcome, while septic shock, need for mechanical ventilation, and length of stay (LOS) were secondary outcomes.ResultsA total of 294 COVID-19 patients were finally studied. Overall prevalence of increased RDW was 49.7% (146/294). RDW was associated with increased risk of in-hospital mortality (aOR, 4.5; 95%CI, 1.4-14.3) and septic shock (aOR, 4.6; 95%CI, 1.4-15.1) after adjusting for anemia, ferritin, and lactate. The association remained unchanged even after adjusting for other clinical confounders such as age, sex, body mass index, coronary artery disease, hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. No association was found instead with mechanical ventilation and median LOS.ConclusionElevated RDW in hospitalized COVID-19 patients is associated with a significantly increased risk of mortality and septic shock.


2019 ◽  
Vol 45 (06) ◽  
pp. 648-656
Author(s):  
Glenn Ramsey ◽  
Paul F. Lindholm

AbstractPatients with cancer have increased risk of thrombosis and often need red blood cell (RBC) transfusions. However, RBC transfusions may also promote thrombosis because of raised hematocrit and viscosity, storage-related RBC damage, and exposure to thrombogenic mediators from obsolescent RBCs. The authors conducted a literature survey for studies examining whether RBC transfusions were associated with increased risk of venous thromboembolism (VTE) in cancer patients. In perioperative cancer surgery patients with categorical comparisons of any versus no RBC transfusion, increased risk of VTE with RBC transfusion was found in 11 of 31 studies, 5 by univariate correlation only and 6 in multivariate analysis. All six multivariate-positive studies had intermediate overall rates of thrombosis (1.4–6.0%), and three were in urological surgery series. In the larger studies of > 2,000 patients (range: 2,219–44,656), the maximum odds ratio among the multivariate-positive studies was 1.3. Perioperative RBC transfusion volume was more strongly associated with VTE risk, with a positive association in six of seven studies. One large registry-based study of hospitalized cancer patients, not restricted to the perioperative setting, found an adjusted odds ratio of 1.60 (95% confidence interval: 1.53–1.67) for VTE risk in patients receiving RBCs compared with nontransfused patients.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3045-3045 ◽  
Author(s):  
Aryeh Shander ◽  
Axel Hofmann ◽  
Sherri Ozawa ◽  
Mazyar Javidroozi

Abstract Complex technical, administrative, and clinical steps involving multiple staff members and various materials and other resources must be successfully completed for a blood transfusion to be given and properly managed. These factors are responsible for the direct and indirect costs of transfusion, which are often overlooked and vastly underestimated. In this study, the total cost of red blood cell (RBC) transfusion process in the surgical setting was calculated through activity-based costing (ABC) in a US hospital as a part of the Cost-of-Blood Consensus Conference (COBCON) project, sponsored by the Society for the Advancement of Blood Management (SABM; Shander et al, Transfus Med Rev.2005;19:66–78). Initially, main transfusion-related processes were identified by observing the “passage” of blood units (from ordering at local blood services to discarding empty bags and expired units) and recipients (for all major pre-, intra- and post-transfusion-related routines performed) through the system. Then, each main process was broken down into serial and parallel activity steps and the frequency (usage factor) and all required resources for each activity were determined. Local cost rates for all resources were retrieved. Specifically developed ABC software modules developed by Medizinische Gesellschaft für Blutmanagement, Laxenburg, Austria in collaboration with IDS-Scheer AG, Germany, based on ARIS Business Architect 7.02 (IDS-Scheer AG, Germany) were used to calculate the cost of each main transfusion process based on these data. Individual processes were condensed, multiplied by usage factor and flow-charted into the total transfusion process, generating the database for hospital‘s total process cost of transfusion. Direct and indirect overhead costs were also calculated and added. All data were validated by appropriate hospital personnel. In 2005, 2413 surgical patients were prepared for potential transfusion, of whom, 461 patients received a total of 1368 blood units (2.97 blood units per surgical patient; 1121 units transfused in ward, 132 in intensive care unit, 69 in operating room/post-anesthesia care unit and 46 in emergency room). RBC units were ordered and transported in bulk from blood services 156 times. Transfusion-related processes with highest usage factor for performing these 461 transfusions are listed in the table. A total of 21 mild or moderate and no severe transfusion reactions were reported. There was no transfusion-related litigation or patient reimbursement due to transfusion errors or complications in the studied period. Based on these data, the total cost of RBC transfusion per patient transfused in the surgical setting of this hospital was US$ 3433. The total cost of a unit of RBC was US$ 1,158 (2007 value), of which, indirect overhead, total transfusion process cost, weighted average acquisition cost and direct overhead cost per unit accounted for 40.6%, 34.0%, 21.5% and 3.9%, respectively. This study shows that the true cost of blood transfusion is much higher than the nominal value currently assigned to each unit of blood. Table: Transfusion-related processes with highest usage factor in surgical setting. Not all processes are listed. Main processes Usage factor/frequency Explaining transfusion risk and obtaining informed consent 13,233 Pre-transfusion examination & clerical routine &gt;2,413 Phlebotomzig & delivering patient’s blood specimen to blood bank & central lab &gt;2,485 Patient blood testing in central lab & analyzing results - routine & emergency &gt;2,413 Controlling & storing components in hospital blood bank 1,445 ABO/Rh-typing new patients &gt;1,330 ABO/Rh-typing control &gt;2,413 Antibody screening &gt;2,413 Cross matching 4,028 manual distribution of components and controlling delivery received at transfusion site 1779 Return deliveries of unused components 633 Cleaning transfusion site & disposing waste &gt;455 Administering and monitoring transfusion 1368


Author(s):  
Long Tran ◽  
Guri Greiff ◽  
Alexander Wahba ◽  
Hilde Pleym ◽  
Vibeke Videm

Abstract Graphical Abstract OBJECTIVES The aim was to compare the relative effects of red blood cell (RBC) transfusion and preoperative anaemia on 5-year mortality following open-heart cardiac surgery using structural equation modelling. We hypothesized that patient risk factors associated with RBC transfusion are of larger importance than transfusion itself. METHODS This prospective cohort study, part of the Cardiac Surgery Outcome Study at St. Olavs University Hospital, Trondheim, Norway, included open-heart on-pump cardiac surgery patients operated on from 2000 through 2017 (n = 9315). Structural equation modelling, which allows for intervariable correlations, was used to analyse pathway diagrams between known risk factors and observed mortality between 30 days and 5 years postoperatively. Observation times between 30 days and 1 year, and 1–5 years postoperatively were also compared with the main analysis. RESULTS In a simplified model, preoperative anaemia had a larger effect on 5-year mortality than RBC transfusion (standardized coefficients: 0.17 vs 0.09). The complete model including multiple risk factors showed that patient risk factors such as age (0.15), anaemia (0.10), pulmonary disease (0.11) and higher creatinine level (0.12) had larger effects than transfusion (0.03). Results from several sensitivity analyses supported the main findings. The models showed good fit. CONCLUSIONS Preoperative anaemia had a larger impact on 5-year mortality than RBC transfusion. Differences in 5-year mortality were mainly associated with patient risk factors.


Sign in / Sign up

Export Citation Format

Share Document